Search Results - "Baez, L. Fulgencio"

Treatment of high‐risk Hodgkin lymphoma with a modified Stanford V regimen in the AHOPCA: Substituting chemotherapy agents and hampered outcomes by Luna‐Fineman, Sandra, Castellanos, Mauricio, Metzger, Monika L., Baez, L. Fulgencio, Peña Hernandez, Armando, Bonilla, Miguel, Fuentes‐Alabi, Soad, Nieves, Rosa, Blanco, Jessica, Rossi, Emanuela, Devidas, Meenakshi, Chen, Yichen, Arreola, Magda, Alarcon, Pedro A.

“…Background/objectives High‐risk Hodgkin lymphoma (HRHL) in children is curable with combined modality therapy. The Association of Pediatric Hematology‐Oncology…”
Get full text

A chemotherapy only therapeutic approach to pediatric Hodgkin lymphoma: AHOPCA LH 1999 by Castellanos, E. Mauricio, Barrantes, José Carlos, Báez, L. Fulgencio, Gamboa, Yessica, Peña, Armando, Alabi, Soad, Bonilla, Miguel, Wang, Huaping, Metzger, Monika L., de Alarcón, Pedro A.

“…Background AHOPCA is a collaborative group that designs uniform treatment regimens (protocols) for children diagnosed with cancer in Central America. Based on…”
Get full text

AMOR: A proposed cooperative effort to improve outcomes of childhood cancer in Central America by Antillon, Federico, Baez, Fulgencio L., Barr, Ronald, Barrantes Zamorra, Jose C., Carrasco, Ligia Fu, Moreno, Belgica, Bonilla, Miguel M., Tognoni, Gianni, Valsecch, Maria G., Howard, Scott, Ribeiro, Raul C., Masera, Giuseppe

“…The dramatic reduction of pediatric cancer mortality rates has been one of the greatest accomplishments of contemporary medicine. About 80% of children with…”
Get full text

A Risk-Adapted, Response-Based Therapeutic Regimen Using a Modified Stanford V Approach for the Treatment of Children with High Risk Hodgkin Lymphoma, AHOPCA LH 2004, a therapeutic regimen from the Central America and Dominican Republic Association of Pediatric Oncology by Castellanos, E. Mauricio, Metzger, Monika, Baez, L. Fulgencio, Gamboa, Yessica, Hernandez, Armando Pena, Alabi, Soad, Luna-Fineman, Sandra, Nieves, Rosa, de Alarcon, Pedro

“…Abstract 718 Hodgkin Lymphoma (HL) is highly curable with reported event-free survival (EFS) estimates of greater than 80% even in high-risk patients…”
Get full text